We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 27, 2019

Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer

The Oncologist


Additional Info

The Oncologist
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups
Oncologist 2019 Oct 10;[EPub Ahead of Print], G Macchia, R Lazzari, N Colombo, C Laliscia, G Capelli, GR D'Agostino, F Deodato, E Maranzano, E Ippolito, S Ronchi, F Paiar, M Scorsetti, S Cilla, R Ingargiola, A Huscher, AM Cerrotta, A Fodor, L Vicenzi, D Russo, S Borghesi, E Perrucci, S Pignata, C Aristei, AG Morganti, G Scambia, V Valentini, BA Jereczek-Fossa, G Ferrandina

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading